deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT02771509

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery

Sponsor: Angion Biomedica Corp

Conditions Acute Kidney Injury
Interventions ANG-3777 Placebo
Updated 17 times since 2017 Last updated: Jul 9, 2021 Started: Feb 24, 2017 Primary completion: Aug 31, 2021 Completion: Aug 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Acute Kidney Injury, this trial is ongoing. The trial is conducted by Angion Biomedica Corp and has accumulated 17 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Aug 2023 · 23 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Aug 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Sep 2021 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 12 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. Jun 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  4. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  5. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  6. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  7. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

    Status: Unknown Status → Recruiting

  8. Jul 2019 — Sep 2019 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  9. Jun 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Angion Biomedica Corp
  • CTI Clinical Trial and Consulting Services
  • Clinical Accelerator
  • Everest Clinical Research
Data source: Angion Biomedica Corp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bethesda, United States , Botucatu, Brazil , Charlottesville, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Durham, United States , Fleming Island, United States and 22 more locations